Cargando…
Long-term safety of aromatase inhibitors in the treatment of breast cancer
Following promising data for metastatic breast cancer in terms of efficacy and safety profile, third-generation aromatase inhibitors (AI), anastrozole, letrozole, and exemestane, underwent a full development in early setting. If recent results consistently show the superiority of these agents over t...
Autor principal: | Nabholtz, Jean-Marc A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2503653/ https://www.ncbi.nlm.nih.gov/pubmed/18728707 |
Ejemplares similares
-
Safety of aromatase inhibitors in the adjuvant setting
por: Perez, Edith A.
Publicado: (2007) -
Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010) -
Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015) -
Aromatase inhibitor treatment for breast cancer: short-term effect on bone health
por: Erbağ, Gökhan, et al.
Publicado: (2015) -
Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor
por: Shioi, Yoshihiro, et al.
Publicado: (2014)